One quarter isn't enough data to be sure, of course. ABBV's 1Q19 HCV sales of $815M were inline with ABBV's 2019 guidance of $3.3B, but GILD's 1Q19 HCV sales of $790M were $90M above the midpoint of GILD's 2019 guidance range of $2.7-2.9B (which was reiterated yesterday), suggesting that subsequent quarters could be somewhat lighter.